Company intelligence / Profile preview

Lion TCR

Singapore, -, Singaporeliontcr.com ↗

Ownership: Private
Employees: ~100
Development stage: Phase 1

Overview

Lion TCR has demonstrated promising safety and efficacy with its lead mRNA-based HBV-specific TCR-T therapy in Phase I studies, showing approximately a threefold increase in survival time compared to standard care for liver cancer patients. The company has received FDA IND approval, Fast Track, and Orphan Drug Designations for its lead asset LioCyx-M004 targeting HBV-related HCC. Ongoing global multicenter Phase II trials are underway. The company’s broader pipeline leverages proprietary platforms to expand into additional solid tumor indications.

Therapeutic areas: OncologyInfectious Diseases
Modalities: T cell receptor (TCR)-T cell therapy (including mRNA-based and gene-edited approaches)mRNA encoding of TCRsAutologous and allogeneic ("off-the-shelf") cell therapies
Industry: Biotech

Drug pipeline

9 assets

liocyx-m

8 more assets in the full pipeline.

Request access →

Partnerships

MaxCyte – partnership to use Flow Electroporation®/ExPERT™ platform to support global expansion/manufacturing scale-up of the pipeline.

Beyond the preview

Go deeper on Lion TCR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lion TCR.

Explore the full profile